According to filings with the U.S. Securities and Exchange Commission, IntraBio is raising up to $40,999,990.00 in new funding. Sources indicate that as part of senior management Chairman, Mallory Factor played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About IntraBio
IntraBio Inc is a private pharmaceutical company located in London, United Kingdom, focusing on drug development and commercialization related to common and rare neurodegenerative diseases, as well as ageing and healthspan. IntraBio’s platform technology results from decades of research and over $350 million of investments from organizations worldwide. Our pipeline has broad applicability to be developed as novel treatments for rare (“orphan”) and common neurological disorders, as well as ageing/extending healthspan. Our lead compound (IB1001) is characterized by a well-established safety and tolerability profile and has a unique potential to address the underlying neurological symptoms and manifestations across a spectrum of genetic and common disorders. IB1001 is initially being developed for multiple orphan indications where there are currently no FDA approved therapies: Niemann-Pick Disease Type C (NPC), GM1 & GM2 Gangliosidosis (Tay-Sachs and Sandhoff Disease), and inherited Cerebellar Ataxias (CA).

To learn more about IntraBio, visit http://intrabio.com/

Contact:
Mallory Factor, Chairman
843-720-0000
https://www.linkedin.com/in/malloryfactor/

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.